$ENTB's primary goal is to continue growing the number of Veterinary Hospitals we own, stated Dr. David Koos, Chairman and CEO of Entest BioMedical. "In pursuing this segment of our business model, we will be able to continue growing our asset base, increase our current revenue stream and establish an initial distribution channel for our products and therapies; the first of these products being Entest's ImenVax immune-therapeutic canine cancer vaccine currently under development.

https://www.yahoo.com/news/entest-biomedical-...00670.html